RPL32P13

Across TCGA pan-cancer cohorts, RPL32P13 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated RPL32P13 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RPL32P13 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL32P13 expression acts as an unfavorable survival marker, although some lineages such as SKCM and BLCA show a favorable association.

LIHC, KIRC, and SKCM are the cancer types where RPL32P13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Quartile	II,III,IV	0.286	0.487	.009	56	view →
KIRC	OS	Median	All	0.746	0.857	<.001	54	view →
SKCM	OS	Median	III,IV	0.801	0.608	<.001	47	view →
BLCA	OS	Median	All	0.813	0.598	.003	43	view →
UVM	OS	Median	All	0.869	0.478	.009	43	view →
KICH	DFS	Tertile	All	0.554	0.955	.002	30	view →
MESO	DFS	Tertile	All	0.664	0.321	.009	29	view →
LUAD	OS	Tertile	III,IV	0.273	0.614	.001	21	view →
THCA	OS	Quartile	III,IV	0.922	0.994	.009	11	view →
ACC	DFS	Tertile	III,IV	0.078	0.414	.039	9	view →
KIRP	DFS	Median	All	0.934	0.806	.004	8	view →
HNSC	DFS	Tertile	All	0.649	0.743	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

RPL32P13–LIHC (OS)

Open the LIHC breakdown →